A Study of Trastuzumab-DM1 Plus Pertuzumab Versus Trastuzumab [Herceptin] Plus a Taxane in Patients With Metastatic Breast Cancer

Inclusion Criteria:

- Adult patients >/=18 years of age

- HER2-positive breast cancer

- Histologically or cytologically confirmed adenocarcinoma of the breast with locally
recurrent or metastatic disease, and be a candidate for chemotherapy. Patients with
locally advanced disease must have recurrent or progressive disease, which must not
be amenable to resection with curative intent.

- Patients must have measurable and/or non-measurable disease which must be evaluable
per RECIST 1.1

- ECOG Performance Status 0 or 1

- Adequate organ function as determined by laboratory results

Exclusion Criteria:

- History of prior (or any) chemotherapy for metastatic breast cancer or recurrent
locally advanced disease

- An interval of <6 months from the last dose of vinca-alkaloid or taxane cytotoxic
chemotherapy until the time of metastatic diagnosis

- Hormone therapy <7 days prior to randomization

- Trastuzumab therapy and/or lapatinib (neo- or adjuvant setting) <21 days prior to
randomization

- Prior trastuzumab emtansine or pertuzumab therapy